CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
falimarev +3 morebiological
Likely dose
Not stated in record
Key inclusion· 6
  • Histologically confirmed hepatic or pulmonary metastases secondary to adenocarcinoma of colon and rectum
  • Complete resection of hepatic or pulmonary metastases with no evidence of gross residual disease
  • At least 2 months of perioperative systemic chemotherapy completed at least 1 month before enrollment
  • Age ≥18 years
Key exclusion· 11
  • History of autoimmune disease including inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis
  • HIV infection (by ELISA and western blot)
  • Immunocompromised by disease or therapy
  • Allergy to eggs, vaccine components, sargramostim (GM-CSF), or prior vaccinia (smallpox) vaccination

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00103142
NCT00103142Phase 2Completed

A Phase II Study of Active Immunotherapy With PANVAC or Autologous, Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma

Michael Morse, MD·interventional·Posted Feb 8, 2005·Updated Oct 14, 2015

In Brief

A Phase 2 clinical trial evaluating falimarev, inalimarev, and 2 other interventions for Colorectal Cancer and Metastatic Cancer. Completed, enrolled 74 participants across 6 sites.

Detailed Summary

RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells. Biological therapies, such as Granulocyte-macrophage colony-stimulating factor (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: This randomized phase II trial is studying giving vaccine therapy together with dendritic cells to see how well it works compared to giving vaccine therapy together with GM-CSF in treating patients with liver or lung metastases from colorectal cancer removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 8, 2005
Enrollment StartFeb 1, 2005
Primary CompletionJun 1, 2009
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 21.4 years ago

Interventions

falimarevbiological

Given subcutaneously and intradermally

inalimarevbiological

Given subcutaneously and intradermally

sargramostimbiological

Given subcutaneously

therapeutic autologous dendritic cellsbiological

Given subcutaneously and intradermally